Chlordiazepoxide Hydrochloride and Clidinium Bromide (Page 4 of 5)
Dependence
Physical Dependence
Chlordiazepoxide hydrochloride and clidinium bromide capsules may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use (see WARNINGS).
To reduce the risk of withdrawal reactions, use a gradual taper to discontinue chlordiazepoxide hydrochloride and clidinium bromide capsules or reduce the dosage (see WARNINGS and DOSAGE AND ADMININSTRATION).
Acute Withdrawal Signs and Symptoms
Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures and suicidality.
Protracted Withdrawal Syndrome
Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used.
Tolerance
Tolerance to chlordiazepoxide hydrochloride and clidinium bromide capsules may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effects of chlordiazepoxide hydrochloride and clidinium bromide capsules may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.
DOSAGE AND ADMINISTRATION
Recommended Dosage
Because of the varied individual responses to tranquilizers and anticholinergics, the optimum dosage of chlordiazepoxide hydrochloride and clidinium bromide capsules varies with the diagnosis and response of the individual patient. The dosage, therefore, should be individualized for maximum beneficial effects. The usual maintenance dose is 1 or 2 capsules, 3 or 4 times a day administered before meals and at bedtime.
Recommended Geriatric Dosage
Dosage should be limited to the smallest effective amount to preclude the development of ataxia, oversedation or confusion. The initial dose should not exceed 2 chlordiazepoxide hydrochloride and clidinium bromide capsules per day, to be increased gradually as needed and tolerated. Elderly patients have an increased risk of dose-related adverse reactions (see PRECAUTIONS).
Discontinuation or Dosage Reduction of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules
To reduce the risk of withdrawal reactions, use a gradual taper to discontinue chlordiazepoxide hydrochloride and clidinium bromide capsules or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly (see WARNINGS and DRUG ABUSE AND DEPENDENCE).
HOW SUPPLIED
Chlordiazepoxide hydrochloride and clidinium bromide capsules are available in light green opaque capsules, each containing 5 mg
chlordiazepoxide hydrochloride and 2.5 mg clidinium bromide in bottles of 100 capsules (NDC 23155-808-01), with “VP302” imprinted on the cap of the capsule.
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Keep this and all medications out of the reach of children.
Dispense in tight, light-resistant container as defined in USP.
Distributed by:
Avet Pharmaceuticals Inc.
East Brunswick, NJ 08816
1.866.901.DRUG (3784)
L41I-ATP, R-2112 Revised : 11/2021
MEDICATION GUIDE
Chlordiazepoxide Hydrochloride (klor” dye az” e pox’ ide hye” droe klor’ ide) and Clidinium Bromide (kli din’ ee um broe’ mide) Capsules, USP For oral use | ||
What is the most important information I should know about chlordiazepoxide hydrochloride and clidinium bromide capsules?
| ||
What are chlordiazepoxide hydrochloride and clidinium bromide capsules?
| ||
Do not take chlordiazepoxide hydrochloride and clidinium bromide capsules if you:
| ||
Before you take chlordiazepoxide hydrochloride and clidinium bromide capsules, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking chlordiazepoxide hydrochloride and clidinium bromide capsules with certain other medicines can cause side effects or affect how well chlordiazepoxide hydrochloride and clidinium bromide capsules or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. Especially tell your healthcare provider if you:
| ||
How should I take chlordiazepoxide hydrochloride and clidinium bromide capsules?
| ||
What are the possible side effects of chlordiazepoxide hydrochloride and clidinium bromide capsules? Chlordiazepoxide hydrochloride and clidinium bromide capsules may cause serious side effects, including: See “What is the most important information I should know about chlordiazepoxide hydrochloride and clidinium bromide capsules?”
The most common side effects of chlordiazepoxide hydrochloride and clidinium bromide capsules include: | ||
|
|
|
|
|
|
| ||
| ||
| ||
| ||
These are not all the possible side effects of chlordiazepoxide hydrochloride and clidinium bromide capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||
How should I store chlordiazepoxide hydrochloride and clidinium bromide capsules?
| ||
General information about the safe and effective use of chlordiazepoxide hydrochloride and clidinium bromide capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take chlordiazepoxide hydrochloride and clidinium bromide capsules for a condition for which it was not prescribed. Do not give chlordiazepoxide hydrochloride and clidinium bromide capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about chlordiazepoxide hydrochloride and clidinium bromide capsules that is written for health professionals. | ||
What are the ingredients in chlordiazepoxide hydrochloride and clidinium bromide capsules? Active ingredients: chlordiazepoxide hydrochloride, USP and clidinium bromide, USP Inactive ingredients: lactose monohydrate, pregelatinized starch, talc. Gelatin capsule shells may contain titanium dioxide with the following dye systems: D&C Yellow #10, FD&C Green #3 and gelatin. Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) Revised : 11/2021 This Medication Guide has been approved by the U.S. Food and Drug Administration. |
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/chlordiazepoxide-hydrochloride-and-clidinium-bromide-2/page/4/